TXG Stock Analysis: 10X Genomics | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 7.524m USD | 12M Return: 316.7% | US88025U1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 144M
Qual. Beats: 0
Rev. Trend: 56.2%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 6.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
10x Genomics, Inc. (NASDAQ: TXG) is a life sciences tools company that develops and sells instruments, consumables, and software for the analysis of biological systems across the United States, the rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The companys product portfolio centers on three platforms: the Chromium single-cell analysis platform (including microfluidic chips, the Chromium X Series, and QuantumScale single cell RNA and methylation kits), the Visium spatial analysis platform (featuring HD gene expression assays and the Visium CytAssist instrument), and the Xenium Analyzer, which enables in situ detection of RNA targets in fresh frozen or FFPE tissue without conventional sequencing. It also offers a software suite, including Cell Ranger for scRNA-seq processing, Loupe Browser for single-cell and spatial data visualization, and Xenium Explorer for subcellular gene expression analysis.
The company serves academic, government, biopharmaceutical, biotechnology, and other research institutions. As a life sciences tools provider, it follows a razor-and-blade business model in which installed instruments drive recurring consumables revenue, a structure common across the sector. Founded in 2012 and headquartered in Pleasanton, California, the company was originally known as 10X Technologies, Inc. before adopting its current name in November 2014, and completed its initial public offering on September 12, 2019.
- Visium and Xenium spatial platforms drive consumables revenue growth
- Biotech funding weakness pressures biopharma instrument orders
- China revenue exposed to export controls and tariffs
| Net Income: -75.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 5.99 > 1.0 |
| NWC/Revenue: 90.15% < 20% (prev 84.32%; Δ 5.83% < -1%) |
| CFO/TA 0.12 > 3% & CFO 127.1m > Net Income -75.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (130.0m) vs 12m ago 4.40% < -2% |
| Gross Margin: 70.03% > 18% (prev 69.50%; Δ 0.53% > 0.5%) |
| Asset Turnover: 61.38% > 50% (prev 65.76%; Δ -4.38% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.54 (Total Current Assets 674.7m - Total Current Liabilities 118.5m) / Total Assets 1.03b |
| B: -1.50 (Retained Earnings -1.54b / Total Assets 1.03b) |
| C: -0.09 (EBIT TTM -88.4m / Avg Total Assets 1.01b) |
| D: 4.04 (Book Value of Equity 825.5m / Total Liabilities 204.5m) |
| Altman-Z'' = 2.31 = BBB |
| DSRI: 0.44 (Receivables 50.6m/119.1m, Revenue 616.9m/644.5m) |
| GMI: 0.99 (GM 69.50% / 70.03%) |
| AQI: 3.62 (AQ_t 0.08 / AQ_t-1 0.02) |
| SGI: 0.96 (Revenue 616.9m / 644.5m) |
| TATA: -0.20 (NI -75.1m - CFO 127.1m) / TA 1.03b) |
| Beneish M = -1.99 (Cap -4..+1) = B |
As of August 17, 2026, the stock is trading at USD 56.09 with a total of 2,007,020 shares traded. Over the past week, the price has changed by +7.80%, over one month by +26.10%, over three months by +161.49% and over the past year by +316.72%.
Current recommended Stop Loss: 51.60 (which is 8% or 1.3 ATR below the current price).
10X Genomics has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold TXG.
- StrongBuy: 5
- Buy: 2
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 48.4 | -13.7% |
P/E Forward = 3333.3333
P/S = 12.1968
P/B = 9.2532
Revenue TTM = 616.9m USD
EBIT TTM = -88.4m USD
EBITDA TTM = -40.4m USD
Long Term Debt = 66.8m USD (estimated: total debt 78.8m - short term 12.0m)
Short Term Debt = 12.0m USD (from shortTermDebt, last quarter)
Debt = 78.8m USD (from shortLongTermDebtTotal, last quarter) (leases 78.8m already included)
Net Debt = -473.2m USD (calculated: Debt 78.8m - CCE 552.0m)
Enterprise Value = 7.05b USD (7.52b + Debt 78.8m - CCE 552.0m)
Interest Coverage Ratio = unknown (Ebit TTM -88.4m / Interest Expense TTM 0.0)
EV/FCF = 58.06x (Enterprise Value 7.05b / FCF TTM 121.4m)
FCF Yield = 1.72% (FCF TTM 121.4m / Enterprise Value 7.05b)
FCF Margin = 19.68% (FCF TTM 121.4m / Revenue TTM 616.9m)
Net Margin = -12.18% (Net Income TTM -75.1m / Revenue TTM 616.9m)
Gross Margin = 70.03% ((Revenue TTM 616.9m - Cost of Revenue TTM 184.9m) / Revenue TTM)
Gross Margin QoQ = 74.48% (prev 70.39%)
Tobins Q-Ratio = 6.85 (Enterprise Value 7.05b / Total Assets 1.03b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 78.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -69.8m (EBIT -88.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.69 (Total Current Assets 674.7m / Total Current Liabilities 118.5m)
Debt / Equity = 0.10 (Debt 78.8m / totalStockholderEquity, last quarter 825.5m)
Debt / EBITDA = 11.70 (negative EBITDA) (Net Debt -473.2m / EBITDA -40.4m)
Debt / FCF = -3.90 (Net Debt -473.2m / FCF TTM 121.4m)
Total Stockholder Equity = 805.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.47% (Net Income -75.1m / Total Assets 1.03b)
RoE = -9.33% (Net Income TTM -75.1m / Total Stockholder Equity 805.3m)
RoCE = -10.13% (EBIT -88.4m / Capital Employed (Equity 805.3m + L.T.Debt 66.8m))
RoIC = -7.82% (negative operating profit) (NOPAT -69.8m / Invested Capital 892.7m)
WACC = 13.18% (E(7.52b)/V(7.60b) * Re(13.32%) + D(78.8m)/V(7.60b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.32% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 99.08 | Cagr: 3.85%
[DCF] Terminal Value 63.97% ; FCFF base≈95.6m ; Y1≈109.6m ; Y5≈161.3m
[DCF] Fair Price = 14.77 (EV 1.30b - Net Debt -473.2m = Equity 1.78b / Shares 120.2m; r=13.18% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.45 | # QB: 0
Revenue Correlation: 56.20 | Revenue CAGR: 1.58% | SUE: 0.38 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.02 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=0.03 | Chg30d=N/A | Revisions=+40% | GrowthEPS=-75.6% | GrowthRev=-3.6%
EPS next Year (2027-12-31): EPS=0.20 | Chg30d=+1.65% | Revisions=+25% | GrowthEPS=+577.8% | GrowthRev=+9.6%
[Analyst] Revisions Ratio: +38% (up=4, down=1)